Daily Archives: October 20, 2022
RCT | Evaluation of mRNA-1273 vaccine in children 6 months to 5 years of age.
20 Oct, 2022 | 12:35h | UTC
Commentary on Twitter
Randomized, placebo-controlled trial of the 2-dose @moderna_tx vaccine in children 6 months to 5 years, during Omicron. Safe in ~4,800 kids; good immune response; efficacy vs infections ?https://t.co/DkLXAQQaeZ @NEJM pic.twitter.com/ettWOnDGQf
— Eric Topol (@EricTopol) October 19, 2022
Myocarditis after BNT162b2 vaccination in Israeli adolescents.
20 Oct, 2022 | 12:34h | UTCMyocarditis after BNT162b2 Vaccination in Israeli Adolescents – New England Journal of Medicine
Commentary on Twitter
Among Israeli adolescents between 12 and 15 years of age who received the BNT162b2 vaccine, 9 cases of mild myocarditis were observed, mainly after the second dose. https://t.co/OatYqN4IPD pic.twitter.com/c96d1o7wnt
— NEJM (@NEJM) October 19, 2022
Perspective | Could, should families watch their loved one’s surgeries and, if so, when?
20 Oct, 2022 | 12:33h | UTCCould, Should Families Watch Their Loved One’s Surgeries and, If So, When? – Anesthesia & Analgesia (free for a limited period)
ASCO Guideline | Treatment of metastatic colorectal cancer.
20 Oct, 2022 | 12:32h | UTCTreatment of Metastatic Colorectal Cancer: ASCO Guideline – Journal of Clinical Oncology
Commentary: ASCO Guideline Highlights Newest Breakthroughs in the Treatment of Metastatic CRC – ASCO Daily News
Commentary on Twitter
‼️ @ASCO Guideline just published: Treatment of Metastatic Colorectal Cancer
Read in #JCO ➡️ https://t.co/CqWdEoSIjd #crcsm #mCRC pic.twitter.com/3N25Fl02v6
— Journal of Clinical Oncology (@JCO_ASCO) October 17, 2022
Clinical practice update for management of acute kidney injury associated with cardiac surgery.
20 Oct, 2022 | 12:31h | UTCSociety of Cardiovascular Anesthesiologists Clinical Practice Update for Management of Acute Kidney Injury Associated With Cardiac Surgery – Anesthesia & Analgesia (free for a limited period)
Commentary on Twitter
The @scahq Clinical Practice Update for Management of Acute Kidney Injury Associated With Cardiac Surgery https://t.co/miFP5MkbnL @iars360
Potential renoprotective benefit:
❤️Goal-directed oxygen delivery on CPB
❤️KDIGO
❤️The use of vasopressin in vasoplegic shock pic.twitter.com/S9O2RtIhIr— Anesthesia&Analgesia (@IARS_Journals) October 13, 2022
M-A | Efficacy and safety of ketamine vs. electroconvulsive therapy among patients with major depressive episode.
20 Oct, 2022 | 12:30h | UTCEfficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode: A Systematic Review and Meta-analysis – JAMA Psychiatry (free for a limited period)
Commentary on Twitter
While #ElectroconvulsiveTherapy may be more efficacious than #ketamine for #depression severity in the acute phase, treatment options should be individualized and patient-centered. https://t.co/4poayVgsTG
— JAMA Psychiatry (@JAMAPsych) October 19, 2022
Review | Update on the management of upper gastrointestinal bleeding.
20 Oct, 2022 | 12:29h | UTCUpdate on the management of upper gastrointestinal bleeding – BMJ Medicine
Cohort Study | Use of straighteners and other hair products and incident uterine cancer.
20 Oct, 2022 | 12:28h | UTCNews Release: Hair straightening chemicals associated with higher uterine cancer risk – NIH News Releases
Commentaries:
Hair-straightening chemical products linked to increased uterine cancer risk in new study – CNN
Hair straightening chemicals may increase women’s risk of uterine cancer, study finds – NPR
Cohort Study | Intravenous potassium and magnesium linked to spontaneous conversion of atrial fibrillation in the ED.
20 Oct, 2022 | 12:27h | UTC
Commentary on Twitter
IV potassium and magnesium was associated with higher rates of conversion in atrial fibrillation but not flutter during patients’ emergency department stays. https://t.co/p3nQK8zNMs
— JAMA Network Open (@JAMANetworkOpen) October 19, 2022
RCT | Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn’s disease.
20 Oct, 2022 | 12:26h | UTCEtrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn’s disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial – The Lancet Gastroenterology & Hepatology (free registration required)
Commentary: Etrolizumab Increases Chance of Clinical Remission for Crohn’s Disease – HCP Live
Commentary on Twitter
New research – Sandborn et al – Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn’s disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial https://t.co/I81bEfz5WU#IBD #GITwitter #UEGWeek pic.twitter.com/lwnl1EI7cz
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) October 12, 2022
Cohort Study | Associations of hypertriglyceridemia onset age with cardiovascular disease and all‐cause mortality in adults.
20 Oct, 2022 | 12:25h | UTC
M-A of RCT | Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis.
20 Oct, 2022 | 12:25h | UTCCarvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis – Journal of Hepatology (link to abstract – $ for full-text)
Commentary on Twitter
#Carvedilol
➡️non-selective #βblocker
✅associated with reduced risk of decompensating events
➡️improved survival in patients with #cirrhosis & #portalhypertensionRead it here?https://t.co/yy8DIJBhfL#LiverTwitter pic.twitter.com/XxmrB7gff8
— Journal of Hepatology (@JHepatology) October 13, 2022
Cohort Study | Genetic sequencing of pancreatic cyst fluid reveals diverse genomic alterations that may guide clinical management.
20 Oct, 2022 | 12:24h | UTCNews Release: Genetic test for pancreatic cancer outperforms current guidelines – University of Pittsburgh
Commentary from the author on Twitter (thread – click for more)
A tweetorial on our study (https://t.co/OCqCRJEMdx). But, first a case: Young female w/ a 1.9 cm incidental pancreatic cyst. No concerning features, but KRAS, TP53 and SMAD4 mutations on molecular testing. Surgical resection: #IPMN w/ a small #PancreaticCancer. #Pathology #GIPath pic.twitter.com/hMJQ4OAUld
— Aatur Singhi, MD PhD (@PancPathologist) October 10, 2022
Cross-sectional study | Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease.
20 Oct, 2022 | 12:22h | UTC
Commentary on Twitter
The Lp(a) Heritage study, in prep for Lp(a) HORIZON, is now out- 48,129 pts eligible otherwise for Lp(a) HORIZON, with survey of Lp(a) levels. Data shows a higher prevalence of ⏫levels in pts with ASCVD vs general population at >70 mg/dL/>150 nmol/L https://t.co/lcp0gSLhCJ pic.twitter.com/DBGBNk0SOa
— Sam Tsimikas, MD (@Lpa_Doc) October 18, 2022
Under a http://creativecommons.org/licenses/by-nc/4.0/ license
Pro-Con Debate | The clinical (Ir)relevance of the lower limit of cerebral autoregulation for anesthesiologists.
20 Oct, 2022 | 12:23h | UTCPro-Con Debate: The Clinical (Ir)relevance of the Lower Limit of Cerebral Autoregulation for Anesthesiologists – Anesthesia & Analgesia (free for a limited period)
Review | Cardiac care of children with Duchenne muscular dystrophy (DMD) and females carrying DMD-gene variations.
20 Oct, 2022 | 12:21h | UTCCardiac care of children with dystrophinopathy and females carrying DMD-gene variations – openheart
Development of a pediatric blood pressure percentile tool for clinical decision support.
20 Oct, 2022 | 12:20h | UTC
Cohort Study | BMI in adolescence and long‐term risk of AF and subsequent mortality, heart failure, and ischemic stroke.
20 Oct, 2022 | 12:20h | UTC
RCT | Lurbinectedin plus Doxorubicin are no better than physician’s choice of chemotherapy in relapsed small-cell lung cancer.
20 Oct, 2022 | 12:19h | UTCCombination lurbinectedin and doxorubicin versus physician’s choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial – The Lancet Respiratory Medicine (link to abstract – $ for full-text)
Commentary on Twitter
NEW—Lurbinectedin + doxorubicin did not improve overall survival vs control in relapsed SCLC., but did show a favourable haematological safety profile
ATLANTIS trial from Prof Luis Paz-Ares & colleagues https://t.co/oF57GJx7u1 pic.twitter.com/8aoqTqXUl7
— The Lancet Respiratory Medicine (@LancetRespirMed) October 17, 2022
Cohort Study | Association of hyperopia with incident clinically significant depression.
20 Oct, 2022 | 12:18h | UTCCommentary: Older Individuals with Hyperopia More Likely to Develop Incident Depression – HCP Live